Finding better ways to screen for gastric cancer in the US
Official title: Assessing feasibility of gastric cancer screening in the US
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11108124 · Data updated 2026-11-12
This study is looking at the best ways to find gastric cancer early in people who are at higher risk, like those with certain age, race, or family history, using advanced technology to help doctors identify who might need screening the most, so we can catch the disease sooner and improve survival rates, especially for different minority groups.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $564,414 |
| NIH project number | 1R37CA300540-01 |
| Project ID | NIH-11108124 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with known risk factors for gastric cancer, such as older adults, those with a family history of the disease, and certain ethnic groups.
✕Less likely to help
Patients who do not have any risk factors for gastric cancer or those already diagnosed with advanced gastric cancer may not benefit from this research.
What this research studies
This research investigates how to effectively screen for gastric cancer in the United States, particularly focusing on high-risk individuals rather than the general population. It aims to develop a targeted screening strategy using electronic health records and machine learning to identify those most likely to benefit from early detection. By understanding risk factors such as age, race, and family history, the study seeks to improve early diagnosis and ultimately enhance survival rates for gastric cancer patients. The research will also address disparities in gastric cancer incidence and mortality among different minority groups.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of gastric cancer, significantly improving survival rates and outcomes for patients.
How similar studies have gone: While similar screening approaches have been successful in other cancers, this specific application of machine learning and electronic health records for gastric cancer screening is relatively novel.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Kim, Michelle Kang — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Kim, Michelle Kang
Related research
Other NIH-funded projects on the same topics.
-
Advancing gastric cancer care for Latinos through patient-derived tumor models
Aimed at Latinos with gastric cancer, this project uses patient-derived tumor models to study how cancer biology and treatments work in real tumors.
-
Circulating metabolites as early warning signs for gastric cancer
Researchers will look at blood-based metabolites to find signs that predict gastric cancer risk in people, with a focus on those in large, multi-center cohorts.
-
Understanding why racial differences exist in stomach cancer in the US
This grant studies why some racial groups in the US have higher stomach cancer rates, focusing on how Helicobacter pylori infection and host responses contribute to these differences.
-
Understanding how gastric cancer starts and grows in the stomach
Researchers at Columbia are studying how two main types of stomach cancer begin and progress, using new mouse models and advanced single-cell and spatial analysis to map where cancer cells come from and how they change.
-
Gastric cancer prevention and screening modeled to guide US care
A nationwide modeling project uses AI and advanced simulations to help decide who should be tested and treated for stomach cancer prevention and screening in the United States.
-
Improved fibrin-targeted radiopharmaceutical for gastric cancer
A new radiopharmaceutical targets fibrin in gastric cancer to help treat advanced disease with potentially fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.